BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36067342)

  • 1. The clinical and economic benefits associated with novel multi-cancer early detection tests: conference highlights from the 2022 ISPOR Annual Meeting.
    Nabavizadeh N
    Am J Manag Care; 2022 Aug; 28(7 Suppl):S123-S132. PubMed ID: 36067342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining developments in multicancer early detection: highlights of new clinical data from recent conferences.
    Beer TM
    Am J Manag Care; 2021 Dec; 27(19 Suppl):S347-S355. PubMed ID: 34870399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK.
    Hackshaw A; Cohen SS; Reichert H; Kansal AR; Chung KC; Ofman JJ
    Br J Cancer; 2021 Nov; 125(10):1432-1442. PubMed ID: 34426664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attitudes to multi-cancer early detection (MCED) blood tests for population-based screening: A qualitative study in Great Britain.
    Schmeising-Barnes N; Waller J; Marlow LAV
    Soc Sci Med; 2024 Apr; 347():116762. PubMed ID: 38520825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mammography screening: A major issue in medicine.
    Autier P; Boniol M
    Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA.
    Tafazzoli A; Ramsey SD; Shaul A; Chavan A; Ye W; Kansal AR; Ofman J; Fendrick AM
    Pharmacoeconomics; 2022 Nov; 40(11):1107-1117. PubMed ID: 36038710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study design considerations for trials to evaluate multicancer early detection assays for clinical utility.
    Minasian LM; Pinsky P; Katki HA; Dickherber T; Han PKJ; Harris L; Patriotis C; Srivastava S; Weil CJ; Prorok PC; Castle PE
    J Natl Cancer Inst; 2023 Mar; 115(3):250-257. PubMed ID: 36458902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening.
    Hackshaw A; Clarke CA; Hartman AR
    Cancer Cell; 2022 Feb; 40(2):109-113. PubMed ID: 35120599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests.
    Gelhorn H; Ross MM; Kansal AR; Fung ET; Seiden MV; Krucien N; Chung KC
    Patient; 2023 Jan; 16(1):43-56. PubMed ID: 35844011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-Cancer Early Detection Tests: Current Progress and Future Perspectives.
    Loomans-Kropp HA; Umar A; Minasian LM; Pinsky PF
    Cancer Epidemiol Biomarkers Prev; 2022 Mar; 31(3):512-514. PubMed ID: 35253043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Principles of Cancer Screening.
    Pinsky PF
    Surg Clin North Am; 2015 Oct; 95(5):953-66. PubMed ID: 26315516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening for cancer: the economic, medical, and psychosocial issues.
    Brill JV
    Am J Manag Care; 2020 Nov; 26(14 Suppl):S300-S306. PubMed ID: 33200894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests.
    Brito-Rocha T; Constâncio V; Henrique R; Jerónimo C
    Cells; 2023 Mar; 12(6):. PubMed ID: 36980276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating cell-free DNA-based multi-cancer early detection.
    Zhang K; Fu R; Liu R; Su Z
    Trends Cancer; 2024 Feb; 10(2):161-174. PubMed ID: 37709615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelled mortality benefits of multi-cancer early detection screening in England.
    Sasieni P; Smittenaar R; Hubbell E; Broggio J; Neal RD; Swanton C
    Br J Cancer; 2023 Jul; 129(1):72-80. PubMed ID: 37185463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.
    Trentham-Dietz A; Kerlikowske K; Stout NK; Miglioretti DL; Schechter CB; Ergun MA; van den Broek JJ; Alagoz O; Sprague BL; van Ravesteyn NT; Near AM; Gangnon RE; Hampton JM; Chandler Y; de Koning HJ; Mandelblatt JS; Tosteson AN;
    Ann Intern Med; 2016 Nov; 165(10):700-712. PubMed ID: 27548583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting.
    Treskova M; Aumann I; Golpon H; Vogel-Claussen J; Welte T; Kuhlmann A
    BMC Med; 2017 Aug; 15(1):162. PubMed ID: 28838313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world cost-effectiveness of stool-based colorectal cancer screening in a Medicare population.
    Fisher DA; Karlitz JJ; Jeyakumar S; Smith N; Limburg P; Lieberman D; Fendrick AM
    J Med Econ; 2021; 24(1):654-664. PubMed ID: 33902366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Tumor DNA Allele Fraction: A Candidate Biological Signal for Multicancer Early Detection Tests to Assess the Clinical Significance of Cancers.
    Bredno J; Venn O; Chen X; Freese P; Ofman JJ
    Am J Pathol; 2022 Oct; 192(10):1368-1378. PubMed ID: 35948080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.